Chemotherapy Regimens: — What the Acronyms Mean

AC combines doxorubicin (the A stands for its former trade name, Adriamycin) and cyclophosphamide. It is used in breast cancer, either before surgery to reduce tumour size or after surgery to lower the risk of recurrence. A typical course runs for four cycles spaced roughly three weeks apart, though your oncologist will confirm the plan for your situation. Main side effects include hair loss, nausea, fatigue, and a temporary fall in white and red blood counts. Your team will check blood counts before each cycle.

TC uses docetaxel (a taxane) and cyclophosphamide. It is used in early breast cancer and is sometimes chosen when avoiding an anthracycline such as doxorubicin is a priority based on a patient's individual risk profile. A typical course runs for four cycles. Docetaxel commonly causes fluid retention, a fall in blood counts, and nerve tingling in the hands and feet. Cyclophosphamide can cause nausea. Your team will explain which side effects to report urgently versus which to monitor at home.

FOLFOX is used mainly in colorectal cancer. It is given intravenously and includes a continuous fluorouracil infusion running over 46 hours, so patients go home attached to a small pump. Cycles are typically every two weeks. Oxaliplatin causes a distinctive cold sensitivity — touching cold objects or drinking cold liquids triggers brief discomfort, particularly early in the course. This usually lessens between cycles. Your team will ask about it before each dose. Cumulative neuropathy is also monitored across the full course.

FOLFIRI substitutes irinotecan for oxaliplatin and is used in colorectal cancer, often when oxaliplatin has already been given or is not tolerated. Irinotecan's main side effect is diarrhoea, which can become severe quickly — any significant increase in bowel frequency must be reported the same day, not waited out. Hair thinning, fatigue, and a fall in blood counts are also common. Like FOLFOX, it includes a 46-hour fluorouracil infusion and a take-home pump.

CAPOX (also called XELOX) combines capecitabine — an oral tablet that converts to fluorouracil in the body — with intravenous oxaliplatin. The oral component means fewer clinic visits than fully intravenous regimens. Capecitabine must be taken at the times your team specifies and must never be stopped without telling your oncologist first. Hand-foot syndrome — redness, soreness, and peeling on the palms and soles — is a common side effect that needs prompt reporting if it limits daily activity.

R-CHOP adds rituximab — a targeted monoclonal antibody — to the CHOP combination of cyclophosphamide, doxorubicin (the H is hydroxydaunorubicin, an older name for doxorubicin), vincristine (Oncovin), and prednisone. It is used for B-cell non-Hodgkin lymphomas. Cycles are typically every three weeks. Vincristine can cause numbness and tingling in the hands and feet. Prednisone raises blood sugar significantly, which requires monitoring in anyone with diabetes. A fall in blood counts between cycles is expected and monitored.

ABVD is a standard regimen for Hodgkin lymphoma. It combines doxorubicin, bleomycin, vinblastine, and dacarbazine. Each cycle is typically four weeks, with treatment given on two days within each cycle. Bleomycin can affect the lungs, and any new breathlessness during ABVD must be reported the same day — this is not a side effect to wait and see about. Nausea, fatigue, and a reduction in blood counts are common. Fertility implications are usually discussed before treatment begins in younger patients.

BEP is used in testicular cancer and other germ cell tumours. Cisplatin can affect hearing and kidney function, both of which are monitored with regular tests during the course. Bleomycin carries a risk of lung toxicity, making any new breathlessness a symptom to report the same day. Nausea from cisplatin is often significant and is managed with anti-nausea medicines given before each day of treatment. Most patients receive BEP as a day-patient or inpatient over several consecutive days per cycle.

GemCis combines gemcitabine and cisplatin and is used in lung, bladder, and biliary tract cancers. Gemcitabine is given intravenously and typically causes fatigue and a fall in blood counts. Cisplatin causes nausea, affects kidney function, and can lead to cumulative hearing changes over repeated cycles. Your team will check kidney function before each cycle, and staying well hydrated on cisplatin days is important. The schedule is typically three-weekly.

FLOT combines four drugs — fluorouracil, leucovorin (folinic acid), oxaliplatin, and docetaxel — and is used in gastric and gastro-oesophageal junction cancers. It carries a broad side-effect load: nausea, diarrhoea, neuropathy from oxaliplatin, hair loss from docetaxel, and a significant fall in blood counts. Cycles are typically every two weeks. Nutrition support from a dietitian is usually recommended alongside treatment, as appetite and eating capacity are often affected during the course.

VCD combines bortezomib (a proteasome inhibitor given as a subcutaneous injection), cyclophosphamide, and dexamethasone (a steroid). It is used in multiple myeloma, often as initial treatment before a stem cell transplant assessment. Bortezomib commonly causes peripheral neuropathy — tingling, numbness, or pain in the hands and feet — which must be reported promptly so your team can review the plan. Dexamethasone raises blood sugar noticeably on the days it is given and can affect mood and sleep.

FOLFIRINOX combines folinic acid, fluorouracil, irinotecan, and oxaliplatin — all four elements — and is used in pancreatic cancer and some other gastrointestinal cancers in patients whose fitness allows a four-drug regimen. It carries a higher overall side-effect burden than two-drug combinations: diarrhoea, nausea, neuropathy, significant fatigue, and a marked fall in blood counts are all common. Close monitoring and same-day reporting of new symptoms are especially important with this combination.